Elizabeth A. Garofalo
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Xenon (XENE) sees insider buying and new analyst price target. Recent filings show insiders purchased more than $1.6 million of XENE shares, marking a notable increase in insider activity. Guggenheim has started coverage of Xenon Pharmaceuticals with a price target of $73, while RBC noted that safety concerns are unlikely to delay the AZK approval pathway. The company also disclosed inducement grants to comply with Nasdaq Listing Rule 5635(c)(4).
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates. RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.
Transaction History
| ALEC | ▲ Buy | Grant | 28,700 | $0 | 6/17/2026 | View on chart |
| XENE | ▲ Buy | Option Exercise | 2,645 | — | 6/1/2026 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 8,107 | — | 5/29/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 1,600 | $42K | 9/2/2025 | View on chart |
| ALEC | ▲ Buy | Grant | 28,700 | $0 | 6/11/2025 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 9,387 | — | 5/29/2025 | View on chart |
| ACAD | ▼ Sell | Open Market | 4,919 | $90K | 3/5/2025 | View on chart |
| ALEC | ▲ Buy | Grant | 35,000 | $0 | 6/12/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 6,652 | — | 5/29/2024 | View on chart |
| XENE | ▲ Buy | Option Exercise | 3,500 | $65K | 3/8/2024 | View on chart |
| XENE | ▼ Sell | Tax Withholding | 1,408 | $65K | 3/8/2024 | View on chart |
| XENE | ▼ Sell | Open Market | 2,092 | $96K | 3/8/2024 | View on chart |
| ALEC | ▼ Sell | Gift | 9,459 | $0 | 12/5/2023 | View on chart |
| ACAD | ▼ Sell | Gift | 2,918 | $0 | 11/24/2023 | View on chart |
| ALEC | ▲ Buy | Grant | 26,250 | $0 | 6/14/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 8,552 | — | 6/1/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,919 | — | 9/29/2022 | View on chart |
| ALEC | ▲ Buy | Grant | 9,459 | $0 | 6/16/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 6,391 | — | 6/7/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,918 | — | 9/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Alector (ALEC) sees purchases by NVIDIA and Merck
Recent filings show that NVIDIA and Merck have added positions in Alector. The involvement of these large technology and pharmaceutical firms may draw attention to the biotech company. The stock is currently trading near its 10‑touch support level of $1.47. Market participants may watch how this institutional interest aligns with the company's valuation.
Alector (ALEC) sees purchases by NVIDIA and Merck. Recent filings show that NVIDIA and Merck have added positions in Alector. The involvement of these large technology and pharmaceutical firms may draw attention to the biotech company. The stock is currently trading near its 10‑touch support level of $1.47. Market participants may watch how this institutional interest aligns with the company's valuation.